Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma

Despite recent advances, metastatic renal cell carcinoma remains largely an incurable disease. Vascular endothelial growth factor and mammalian target of rapamycin inhibitors have provided improvements in clinical outcomes. High-dose interleukin 2 remains an option for highly selected patients and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonpavde, G, Choueiri, T K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461173/
https://www.ncbi.nlm.nih.gov/pubmed/22948724
http://dx.doi.org/10.1038/bjc.2012.399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461173/
https://www.ncbi.nlm.nih.gov/pubmed/22948724
http://dx.doi.org/10.1038/bjc.2012.399

Ejemplares similares